Validation of group B borderline resectable pancreatic cancer

Retrospective analysis

Tak Geun Oh, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Jae Bok Chung, Si Young Song, Jinsil Seong, ChangMoo Kang, Woo Jung Lee, Jeong Youp Park

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: Among borderline resectable pancreatic cancer (BRPC), group B BRPC patients have findings that are suggestive but not diagnostic of metastasis. In this study, we attempted to validate whether group B could truly be categorized as a borderline resectable group. Methods: We placed the BRPC patients into group A or group B. The survival outcomes were compared between the groups. Results: A total of 53 patients with pancreatic adenocarcinoma was classified as either group A or B borderline resectable. In group A, 23 (60.5%) of 38 patients underwent pancreatectomy after concurrent chemoradiotherapy or chemotherapy, but in group B, only five (33.3%) of 15 patients underwent pancreatectomy, mainly because of the progression of suspected distant metastasis. There was a significant difference in overall survival (OS) between group A and B patients (median OS, 21.2 months vs 10.2 months, respectively; p=0.007). Of the patients who underwent pancreatectomy, group B had a higher recurrence rate compared to group A (recurrence rate: 11 of 23 patients [47.8%] vs five of five patients [100%], respectively; p=0.033). Conclusions: This report is the first to validate the definition of BPRC. Group B had much worse outcomes, and whether group B BRPC can be categorized as BRPC together with group A is questionable.

Original languageEnglish
Pages (from-to)557-562
Number of pages6
JournalGut and Liver
Volume8
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Pancreatic Neoplasms
Pancreatectomy
Survival
Neoplasm Metastasis
Recurrence
Chemoradiotherapy
Adenocarcinoma
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Oh, T. G., Chung, M. J., Bang, S., Park, S. W., Chung, J. B., Song, S. Y., ... Park, J. Y. (2014). Validation of group B borderline resectable pancreatic cancer: Retrospective analysis. Gut and Liver, 8(5), 557-562. https://doi.org/10.5009/gnl13264
Oh, Tak Geun ; Chung, Moon Jae ; Bang, Seungmin ; Park, Seung Woo ; Chung, Jae Bok ; Song, Si Young ; Seong, Jinsil ; Kang, ChangMoo ; Lee, Woo Jung ; Park, Jeong Youp. / Validation of group B borderline resectable pancreatic cancer : Retrospective analysis. In: Gut and Liver. 2014 ; Vol. 8, No. 5. pp. 557-562.
@article{d9b92b108b3746c78f51f78fbc6146db,
title = "Validation of group B borderline resectable pancreatic cancer: Retrospective analysis",
abstract = "Background/Aims: Among borderline resectable pancreatic cancer (BRPC), group B BRPC patients have findings that are suggestive but not diagnostic of metastasis. In this study, we attempted to validate whether group B could truly be categorized as a borderline resectable group. Methods: We placed the BRPC patients into group A or group B. The survival outcomes were compared between the groups. Results: A total of 53 patients with pancreatic adenocarcinoma was classified as either group A or B borderline resectable. In group A, 23 (60.5{\%}) of 38 patients underwent pancreatectomy after concurrent chemoradiotherapy or chemotherapy, but in group B, only five (33.3{\%}) of 15 patients underwent pancreatectomy, mainly because of the progression of suspected distant metastasis. There was a significant difference in overall survival (OS) between group A and B patients (median OS, 21.2 months vs 10.2 months, respectively; p=0.007). Of the patients who underwent pancreatectomy, group B had a higher recurrence rate compared to group A (recurrence rate: 11 of 23 patients [47.8{\%}] vs five of five patients [100{\%}], respectively; p=0.033). Conclusions: This report is the first to validate the definition of BPRC. Group B had much worse outcomes, and whether group B BRPC can be categorized as BRPC together with group A is questionable.",
author = "Oh, {Tak Geun} and Chung, {Moon Jae} and Seungmin Bang and Park, {Seung Woo} and Chung, {Jae Bok} and Song, {Si Young} and Jinsil Seong and ChangMoo Kang and Lee, {Woo Jung} and Park, {Jeong Youp}",
year = "2014",
month = "1",
day = "1",
doi = "10.5009/gnl13264",
language = "English",
volume = "8",
pages = "557--562",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "5",

}

Oh, TG, Chung, MJ, Bang, S, Park, SW, Chung, JB, Song, SY, Seong, J, Kang, C, Lee, WJ & Park, JY 2014, 'Validation of group B borderline resectable pancreatic cancer: Retrospective analysis', Gut and Liver, vol. 8, no. 5, pp. 557-562. https://doi.org/10.5009/gnl13264

Validation of group B borderline resectable pancreatic cancer : Retrospective analysis. / Oh, Tak Geun; Chung, Moon Jae; Bang, Seungmin; Park, Seung Woo; Chung, Jae Bok; Song, Si Young; Seong, Jinsil; Kang, ChangMoo; Lee, Woo Jung; Park, Jeong Youp.

In: Gut and Liver, Vol. 8, No. 5, 01.01.2014, p. 557-562.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Validation of group B borderline resectable pancreatic cancer

T2 - Retrospective analysis

AU - Oh, Tak Geun

AU - Chung, Moon Jae

AU - Bang, Seungmin

AU - Park, Seung Woo

AU - Chung, Jae Bok

AU - Song, Si Young

AU - Seong, Jinsil

AU - Kang, ChangMoo

AU - Lee, Woo Jung

AU - Park, Jeong Youp

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background/Aims: Among borderline resectable pancreatic cancer (BRPC), group B BRPC patients have findings that are suggestive but not diagnostic of metastasis. In this study, we attempted to validate whether group B could truly be categorized as a borderline resectable group. Methods: We placed the BRPC patients into group A or group B. The survival outcomes were compared between the groups. Results: A total of 53 patients with pancreatic adenocarcinoma was classified as either group A or B borderline resectable. In group A, 23 (60.5%) of 38 patients underwent pancreatectomy after concurrent chemoradiotherapy or chemotherapy, but in group B, only five (33.3%) of 15 patients underwent pancreatectomy, mainly because of the progression of suspected distant metastasis. There was a significant difference in overall survival (OS) between group A and B patients (median OS, 21.2 months vs 10.2 months, respectively; p=0.007). Of the patients who underwent pancreatectomy, group B had a higher recurrence rate compared to group A (recurrence rate: 11 of 23 patients [47.8%] vs five of five patients [100%], respectively; p=0.033). Conclusions: This report is the first to validate the definition of BPRC. Group B had much worse outcomes, and whether group B BRPC can be categorized as BRPC together with group A is questionable.

AB - Background/Aims: Among borderline resectable pancreatic cancer (BRPC), group B BRPC patients have findings that are suggestive but not diagnostic of metastasis. In this study, we attempted to validate whether group B could truly be categorized as a borderline resectable group. Methods: We placed the BRPC patients into group A or group B. The survival outcomes were compared between the groups. Results: A total of 53 patients with pancreatic adenocarcinoma was classified as either group A or B borderline resectable. In group A, 23 (60.5%) of 38 patients underwent pancreatectomy after concurrent chemoradiotherapy or chemotherapy, but in group B, only five (33.3%) of 15 patients underwent pancreatectomy, mainly because of the progression of suspected distant metastasis. There was a significant difference in overall survival (OS) between group A and B patients (median OS, 21.2 months vs 10.2 months, respectively; p=0.007). Of the patients who underwent pancreatectomy, group B had a higher recurrence rate compared to group A (recurrence rate: 11 of 23 patients [47.8%] vs five of five patients [100%], respectively; p=0.033). Conclusions: This report is the first to validate the definition of BPRC. Group B had much worse outcomes, and whether group B BRPC can be categorized as BRPC together with group A is questionable.

UR - http://www.scopus.com/inward/record.url?scp=84906243754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906243754&partnerID=8YFLogxK

U2 - 10.5009/gnl13264

DO - 10.5009/gnl13264

M3 - Article

VL - 8

SP - 557

EP - 562

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 5

ER -

Oh TG, Chung MJ, Bang S, Park SW, Chung JB, Song SY et al. Validation of group B borderline resectable pancreatic cancer: Retrospective analysis. Gut and Liver. 2014 Jan 1;8(5):557-562. https://doi.org/10.5009/gnl13264